M
Masoud Najafi
Researcher at Kermanshah University of Medical Sciences
Publications - 200
Citations - 8663
Masoud Najafi is an academic researcher from Kermanshah University of Medical Sciences. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 36, co-authored 165 publications receiving 4394 citations. Previous affiliations of Masoud Najafi include Shiraz University of Medical Sciences & Tehran University of Medical Sciences.
Papers
More filters
Journal ArticleDOI
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review.
TL;DR: CD8 + T cell priming is directed essentially as a corroboration work between cells of innate immunity including dendritic cells (DCs) and natural killer (NK) cells with CD4 + T cells in adoptive immunity for making durable and efficient antitumor immune responses.
Journal ArticleDOI
Cyclooxygenase-2 in cancer: A review.
TL;DR: Choosing an appropriate chemotherapy drugs along with adjustment of the type and does for COX‐2 inhibitors based on the type of cancer would be an effective adjuvant strategy for targeting cancer.
Journal ArticleDOI
Macrophage polarity in cancer: A review.
Masoud Najafi,Nasser Hashemi Goradel,Bagher Farhood,Eniseh Salehi,Maryam Shabani Nashtaei,Neda Khanlarkhani,Zahra Khezri,Jamal Majidpoor,Morteza Abouzaripour,Mohsen Habibi,Iraj Ragerdi Kashani,Keywan Mortezaee +11 more
TL;DR: Macrophage switching toward an anti‐inflammatory M1 phenotype could be used as an adjuvant with other approaches, including radiotherapy and immune checkpoint blockades, such as anti‐PD‐L1/PD‐1 strategies.
Journal ArticleDOI
Cancer stem cells (CSCs) in cancer progression and therapy.
TL;DR: There are multiple ways to target CSCs, including immunotherapy, hormone therapy, (mi)siRNA delivery, and gene knockout, which can be designed for suppressing CSC stemness, tumorigenic cues from TME, CSC extrinsic and/or intrinsic signaling, hypoxia or for promoting differentiation in the cells.
Journal ArticleDOI
Extracellular matrix (ECM) stiffness and degradation as cancer drivers.
TL;DR: MMP and TGF‐β inhibitors, CAF and M2 reprogramming toward their normal counterparts, reduction of TME hypoxia and hampering integrin signaling are among the promising approaches for the modulation of ECM in favor of tumor regression.